Tuesday, September 24, 2024 7:38:54 AM
up 200% on SMMT and adding shares on ICCM every day. Founder Victor Lee of Tencent owns 55% of Icecure shares similar to Duggan at SMMT who owns a majority of SMMT shares.
Interesting Cancer Platform Remember SMMT was a $1.00 early this year ICCM has 5 year data by half a dozen countries running independent studies safer have less side affects and much better efficacy than medicine on the market today. IceCure Freezes and Kills Tumors across the board Breast, Kidney and Lung Tumors.
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
The study titled "Liquid Nitrogen-Based Cryoablation: Complication Rates for Lung, Bone, and Soft Tissue Tumors" was published by Oxford University Press on behalf of the British Institute of Radiology.
https://ir.icecure-medical.com/news-events/press-releases/detail/144/study-published-in-the-british-journal-of-radiology-demonstrates-icecures-prosense-is-a-safe-procedure-with-97-7-technical-success-rate-in-treating-tumors-of-the-lung-bone-and-soft-tissues
FDA Panel Meeting soon and FDA Approval slated for December 20024 or January 2025 for Breast Cancer.
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
https://ir.icecure-medical.com/news-events/press-releases/detail/139/icecures-prosense-destroyed-100-of-breast-cancer-tumors-in-independent-study-of-patients-who-chose-cryoablation-instead-of-surgery
SMMT market cap 20 Billion SMMt was under a Billion market cap earlier this year.
IceCure ICCM 30 Million market cap
$SMMT
Interesting Cancer Platform Remember SMMT was a $1.00 early this year ICCM has 5 year data by half a dozen countries running independent studies safer have less side affects and much better efficacy than medicine on the market today. IceCure Freezes and Kills Tumors across the board Breast, Kidney and Lung Tumors.
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
The study titled "Liquid Nitrogen-Based Cryoablation: Complication Rates for Lung, Bone, and Soft Tissue Tumors" was published by Oxford University Press on behalf of the British Institute of Radiology.
https://ir.icecure-medical.com/news-events/press-releases/detail/144/study-published-in-the-british-journal-of-radiology-demonstrates-icecures-prosense-is-a-safe-procedure-with-97-7-technical-success-rate-in-treating-tumors-of-the-lung-bone-and-soft-tissues
FDA Panel Meeting soon and FDA Approval slated for December 20024 or January 2025 for Breast Cancer.
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
https://ir.icecure-medical.com/news-events/press-releases/detail/139/icecures-prosense-destroyed-100-of-breast-cancer-tumors-in-independent-study-of-patients-who-chose-cryoablation-instead-of-surgery
SMMT market cap 20 Billion SMMt was under a Billion market cap earlier this year.
IceCure ICCM 30 Million market cap
$SMMT
Bullish
Recent SMMT News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/17/2026 09:00:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/17/2026 08:12:22 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/06/2026 08:28:53 PM
- Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 • Business Wire • 03/27/2026 12:15:00 PM
- Summit Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 02/26/2026 11:45:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2026 09:58:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/23/2026 09:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:07:53 PM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 • Business Wire • 02/23/2026 09:05:00 PM
- Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 • Business Wire • 02/17/2026 10:05:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/30/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:35:03 PM
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy • Business Wire • 01/29/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2026 09:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 12:43:04 PM
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) • Business Wire • 01/12/2026 11:15:00 AM
- Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC • Business Wire • 01/12/2026 11:00:00 AM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/10/2026 01:16:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 11:52:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 11:39:57 PM
- Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/06/2026 12:30:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/05/2025 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 02:23:15 PM
- Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China • Business Wire • 11/07/2025 02:00:00 PM
- Summit Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 11/04/2025 12:00:00 PM
